Skip to main content

Table 1 Parameters used in the analysis

From: The global impact and cost-effectiveness of a melioidosis vaccine

  Values References
Risk of melioidosis (baseline) See Additional file 1: Table S3(a)  
Relative risk of melioidosis by risk factor
 - Age > 45 years 2.01 (1.87, 2.15) Estimated from literature
 - Diabetes 6.50 (6.10, 6.93) Estimated from literature
 - Chronic renal disease 1.33 (1.20, 1.46) Estimated from literature
Probability of each condition given melioidosis infection (3 levels; high-, middle- and low-income geographies) High Middle Low  
 Probability of acute disease with complications 0.40 0.50 0.25 Expert opinion
 Probability of acute disease without complications 0.48 0.40 0.55 Expert opinion
 Probability of chronic disease with systemic illness 0.07 0.05 0.07 Expert opinion
 Probability of chronic disease without systemic illness 0.06 0.05 0.12 Expert opinion
Risk of death (relative risk for each condition)
 Baseline risk of death (chronic disease without systemic illness) Vary between geographies Estimated
 Relative risk for acute disease with complications 16.42 Expert opinion
 Relative risk for acute disease without complications 5.33 Expert opinion
 Relative risk of chronic disease with systemic illness 5.17 Expert opinion
Probability of intensive care unit admission among acute cases with complication 0.62 (0.48, 0.75) Expert opinion
Economic parameters
 Resource use
  Length of hospital stay (LOS) Median (95% CI) Indian hospital data
   Intensive care unit (ICU) for acute disease with complication cases 3.20 (0.58, 10.04)  
   General hospitalisation   
    - Acute disease with complication 13.85 (1.66, 34.71)  
    - Acute disease without complication 14.77 (2.51, 34.35)  
    - Chronic disease with systemic illness 18.19 (4.20, 41.61)  
    - Chronic disease without systemic illness 15.36 (1.06, 41.81)  
  Treatment duration (days) [10]
   - Parenteral regimens 12 (10, 14)  
    Meropenem or ceftazidime   
   - Oral regimens 112 (84, 140)  
    Trimethroprim/sulfamethoxazole or co-amoxiclav   
Costs (USD, 2016)
 Cost of vaccine (complete course) by country income level Low 10.2
Middle 43.5
High 338.2
[27]
 Cost per bed day WHO-CHOICE [31]
 Cost per ICU bed day
  Ratio between ICU and general bed day by income level High 2.56
Middle 7.92
Low 13.28
See Additional file 1: Table S3(b)
Antibiotics (per day), children aged < 15 years High Middle Low  
 Meropenem 46.78 59.47 N/A [32, 33]
 Ceftazidime 27.89 3.44 3.44  
 Trimethoprim/sulfamethoxazole 0.91 0.05 0.05  
 Co-amoxiclav 0.71 1.41 1.41  
Antibiotics (per day), adults aged > 15 years High Middle Low  
 Meropenem 62.37 79.30 N/A [32, 33]
 Ceftazidime 43.39 5.35 5.35  
 Trimethoprim/sulfamethoxazole 1.12 0.06 0.06  
 Co-amoxiclav 1.06 2.11 2.11  
Health-related quality of life (utility)   
 Bacteraemia 0.36 (0.33, 0.38) [28]
 General population 0.84 [29]
Life expectancy WHO Life Table [23]